Mr Mrs Miss Ms Dr Other

Dr
Delphine
Lauté-Caly

Trainee Patent Attorney

Aberdeen Office

Life sciences

Telephone. +44 (0)1224 258 510
Email. [email protected]
Vcard
Linkedin

Experience

Delphine joined HGF's Aberdeen office in August 2023 as a Trainee Patent Attorney within the Life Sciences team. She has a strong scientific background, with more than 15 years experience in both academic and industry settings.

She holds a PhD in Microbiology from University College Cork and Master's degrees in Food Sciences and Bioprocesses from Université de Lille in France.

During her post-doctoral positions in Ireland and France, she specialised in molecular microbiology, studying gene regulation and protein expression in bacterial pathogens and probiotics.

Delphine has extensive knowledge of the human microbiome and bacterial engineering. She worked for 7 years in a microbiome therapeutics company, where her work focused on the mechanism of action of live biotherapeutic products and the genetic manipulation of non-model microorganisms.

Specialisms

Industries

Services

Qualifications

Trainee

MSC

MSc in Bioprocesses and Biotechnologies

MSC

MSc in Agri-food Engineering

PHD

PhD in Microbiology

Related News

Event - 8th, 22nd February 2024

Dresden & Salzburg Seminar: Basics of trade mark protection - National and European perspectives

HGF is pleased to invite you to our upcoming German speaking seminar on “Fundamentals of trade mark protection: National and European Perspectives” in Salzburg and Dresden. The seminar will cover …

Event details

EPO Annual Fee Increases

The European Patent Office (EPO) has announced that revised Official Fees will apply to payments made on or after Monday 1st April 2024. The majority of fees will increase by …

Read article
Event - 30th January 2024

CAR-TCR Summit, Europe 2024

HGF are proud Event Partners of CAR-TCR Europe, which is due to go ahead from 27th – 29th February at ExCeL, Royal Victoria Dock in London. This is the European hub …

Event details

First CRISPR therapy approved for use in the UK

In an unprecedented move, the MHRA has approved a CRISPR gene editing therapy ‘Casgevy’  for the treatment of sickle cell disease and beta-thalassaemia in patients with recurrent vaso-occlusive crises. The Casgevy …

Read article
Event - 8th, 22nd February 2024

Dresden & Salzburg Seminar: Invention and patent searches in public databases

HGF is pleased to invite you to our upcoming German-language seminar on “Invention and patent searches in public databases” in Salzburg and Dresden. The seminar will showcase how public databases …

Event details
Event - 29th November 2023

HGF & Shiga Webinar Recording: Medical devices and bioinformatics / AI diagnostic feedback - law and practice in Europe and Japan

“Medical devices and bioinformatics / AI diagnostic feedback – law and practice in Europe and Japan” The EPC does not allow ‘medical use’ claims for medial devices. So how do …

Event details

Blog Series: IP Ingredients, Part 1: Can you patent a recipe?

A patent is a legal right that enables the patent holder to prevent others from making and using their invention in the country where the patent is granted.  To many …

Read article

UPC and Forum Shopping – Rule 17.3

Order of the classifications listed on the front of a patent and why it matters? On 1 June 2023, ASTELLAS INSTITUTE FOR REGENERATIVE MEDICINE lodged a statement of revocation of …

Read article
See all updates

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.

Contact us